A detailed history of Moody Aldrich Partners LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Moody Aldrich Partners LLC holds 84,907 shares of ALKS stock, worth $2.54 Million. This represents 0.47% of its overall portfolio holdings.

Number of Shares
84,907
Previous 62,066 36.8%
Holding current value
$2.54 Million
Previous $1.5 Million 58.93%
% of portfolio
0.47%
Previous 0.32%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

BUY
$23.01 - $28.55 $525,571 - $652,110
22,841 Added 36.8%
84,907 $2.38 Million
Q2 2024

Jul 23, 2024

SELL
$23.21 - $27.24 $96,135 - $112,828
-4,142 Reduced 6.26%
62,066 $1.5 Million
Q1 2024

Apr 29, 2024

BUY
$26.4 - $32.56 $360,043 - $444,053
13,638 Added 25.94%
66,208 $1.79 Million
Q4 2023

Jan 25, 2024

BUY
$23.37 - $28.68 $292,031 - $358,385
12,496 Added 31.18%
52,570 $1.46 Million
Q3 2023

Nov 07, 2023

BUY
$27.17 - $31.97 $1.09 Million - $1.28 Million
40,074 New
40,074 $1.12 Million

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.92B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Moody Aldrich Partners LLC Portfolio

Follow Moody Aldrich Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Moody Aldrich Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Moody Aldrich Partners LLC with notifications on news.